Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14128893 | 0.92 | NPSR1 (0.40) | NPSR1ALDH1A1LMNAMAPTCYP4F2 | |
| SCHEMBL30683834 | 0.90 | NPSR1 (0.48) | NPSR1ALDH1A1LMNAMAPTCYP4F2 | |
| SCHEMBL11378685 | 0.88 | NPSR1 (0.47) | NPSR1ALDH1A1LMNAMAPTCYP4F2 | |
| SCHEMBL225044 | 0.86 | NPSR1 (0.46) | NPSR1ALDH1A1LMNAMAPTCYP4F2 | |
| SCHEMBL12462298 | 0.86 | NPSR1 (0.46) | NPSR1ALDH1A1LMNAMAPTCYP4F2 | |
| SCHEMBL1662363 | 0.84 | CYP3A4 (0.41) | NPSR1ALDH1A1LMNAMAPTCYP4F2 | |
| SCHEMBL8950528 | 0.80 | TP53 (0.40) | ALDH1A1MAPTGAA | |
| SCHEMBL17117827 | 0.79 | TSHR (0.30) | — | |
| SCHEMBL71320 | 0.79 | NPSR1 (0.41) | NPSR1ALDH1A1LMNAMAPTCYP4F2 | |
| SCHEMBL2517854 | 0.77 | NPSR1 (0.45) | NPSR1ALDH1A1LMNAMAPTCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734983-A2 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | Engrail Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4656638-A2 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| CN-116730849-B | Preparation method of optically active [1- (1-amino ethyl) cyclopropyl ] methanol | 江苏艾迪药业股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2025010255-A2 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | ENGRAIL THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4444316-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024153180-A1 | HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-6613935-B2 | Reacting a beta-ketoester derivative such as an acetoacetate with 1,2-dichloroethane that is readily available at low cost | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| EP-1300389-A2 | Process for producing 1-acyl-1-cyclopropanecarboxylate derivatives | Daicel Chemical Industries, Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20030065212-A1 | Process for producing 1-acyl-1-cyclopropanecarboxylate derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | STEINMEYER ANDREAS (DE) | 2003-01-23 | — | — | US | disclosed |
| US-6376480-B1 | TREATMENT OF IMMUNE SYSTEM DISORDERS, OSTEOPOROSIS, ALOPECIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-23 | — | — | US | disclosed |
| US-6372731-B1 | TREATMENT OF CELL PROLIFERATION AND BONE DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-16 | — | — | US | disclosed |
| CN-1042026-C | 25Carboxylic derivative of vitamin D series, middle products in production of same and pharmaceutical containing same and use of same in treatment | SCHERING AG (DE) | 1999-02-10 | — | — | CN | disclosed |
| US-5583125-A | SKIN DISORDERS, ANTITUMOR AGENTS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-12-10 | — | — | US | disclosed |
| CN-1094034-A | 25 carboxylic acid derivative of vitamin D series, its method for making and intermediate product, contain the medicine of this derivative and medicinal | SCHERING AG (DE) | 1994-10-26 | — | — | CN | disclosed |
| EP-0354757-A2 | Cephalosporins and homologous compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | PIKFYVE, TARDBP, TDP1 | NPSR1 4137/4885ALDH1A1 4792/4885LMNA 3043/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | NPSR1 2407/4885ALDH1A1 1200/4885LMNA 4349/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | NPSR1 3090/4885ALDH1A1 300/4885LMNA 4091/4885 |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | CYP2R1, CYP24A1, VDR | NPSR1 1330/4885ALDH1A1 599/4885LMNA 3126/4885 |
| US-20030065212-A1 | Process for producing 1-acyl-1-cyclopropanecarboxylate derivatives | DHCR24, CYP1A1, CYP51A1 | NPSR1 3270/4885ALDH1A1 124/4885LMNA 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.